Abstract
Processing of antigens within antigen presenting cells (APCs) is necessary for an immune response. Two pathways exist to present antigens to T cells: the major histocompatibility complex class I (MHC I) pathway to activate cytotoxic T cells (CTLs) and the MHC II route to stimulate T helper cells (Ths). Prior to efficient antigen presentation to MHC II, antigens have to be proteolytically degraded by proteases, the cathepsins, inside the endocytic compartment of APCs. Cathepsins process both antigens and self-antigens to antigenic peptides; the latter are critical for autoimmunity. Remarkably, distribution, substrate specificity, and function of cathepsins located in the antigen processing machinery depend on the cell type, primary or cultured cells, or species analyzed. However, a precise understanding of the antigen processing and presentation machinery is needed to generate specific immune modulators since the MHC antigen- processing pathway is subsequently regulated during tumorigenesis, infection, or autoimmunity. In this review, the latest finding regarding function and regulation of the MHC II proteolytic machinery and its possible target for immunomodulation will be discussed.
Keywords: Antigen processing and presentation, major histocompatibility complex, cathepsin, cathepsin-specific inhibitors, dendritic cells, B cells, immunomodulation.
Current Pharmaceutical Design
Title:Processing and Regulation Mechanisms within Antigen Presenting Cells: A Possibility for Therapeutic Modulation
Volume: 19 Issue: 6
Author(s): Timo Burster
Affiliation:
Keywords: Antigen processing and presentation, major histocompatibility complex, cathepsin, cathepsin-specific inhibitors, dendritic cells, B cells, immunomodulation.
Abstract: Processing of antigens within antigen presenting cells (APCs) is necessary for an immune response. Two pathways exist to present antigens to T cells: the major histocompatibility complex class I (MHC I) pathway to activate cytotoxic T cells (CTLs) and the MHC II route to stimulate T helper cells (Ths). Prior to efficient antigen presentation to MHC II, antigens have to be proteolytically degraded by proteases, the cathepsins, inside the endocytic compartment of APCs. Cathepsins process both antigens and self-antigens to antigenic peptides; the latter are critical for autoimmunity. Remarkably, distribution, substrate specificity, and function of cathepsins located in the antigen processing machinery depend on the cell type, primary or cultured cells, or species analyzed. However, a precise understanding of the antigen processing and presentation machinery is needed to generate specific immune modulators since the MHC antigen- processing pathway is subsequently regulated during tumorigenesis, infection, or autoimmunity. In this review, the latest finding regarding function and regulation of the MHC II proteolytic machinery and its possible target for immunomodulation will be discussed.
Export Options
About this article
Cite this article as:
Burster Timo, Processing and Regulation Mechanisms within Antigen Presenting Cells: A Possibility for Therapeutic Modulation, Current Pharmaceutical Design 2013; 19 (6) . https://dx.doi.org/10.2174/1381612811319060005
DOI https://dx.doi.org/10.2174/1381612811319060005 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HS-MMGKG: A Fast Multi-objective Harmony Search Algorithm for Two-locus Model Detection in GWAS
Current Bioinformatics Emerging Hsp90 Inhibitors: From Discovery to Clinic
Anti-Cancer Agents in Medicinal Chemistry Peptides as Therapeutic Agents or Drug Leads for Autoimmune, Hormone Dependent and Cardiovascular Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Genistein Potentiates the Anti-cancer Effects of Gemcitabine in Human Osteosarcoma via the Downregulation of Akt and Nuclear Factor-κB Pathway
Anti-Cancer Agents in Medicinal Chemistry RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer
Current Cancer Drug Targets Trafficking of Neuronal Two Pore Domain Potassium Channels
Current Neuropharmacology In Silico Design of Protein Kinase Inhibitors: Successes and Failures
Anti-Cancer Agents in Medicinal Chemistry Molecular Dynamics as a Tool in Rational Drug Design: Current Status and Some Major Applications
Current Computer-Aided Drug Design Small Molecules in Cancer Therapy: Cytotoxics and Molecularly Targeted Agents
Current Signal Transduction Therapy Study of drug-drug combinations based on molecular descriptors and physicochemical properties
Combinatorial Chemistry & High Throughput Screening Bioavailability Enhancement Strategies: Basics, Formulation Approaches and Regulatory Considerations
Current Drug Delivery Receptor Proteins for Nongenomic Actions of Thyroid Hormone
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A Review on Biological Activities and Chemical Synthesis of Hydrazide Derivatives
Current Medicinal Chemistry The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases
Current Medicinal Chemistry In Vivo Pharmacokinetic and Tissue Distribution Studies in Mice of Alternative Formulations for Local and Systemic Delivery of Paclitaxel: Gel, Film, Prodrug, Liposomes and Micelles
Current Drug Delivery QSAR Study and Design of Novel Organoselenium and α-Tocopherol Derivatives with Enhanced Chemotherapeutic Activity
Letters in Drug Design & Discovery Recombinant Salmonella Vaccination Technology and Its Application to Human Bacterial Pathogens
Current Pharmaceutical Biotechnology Induction of Antitumor Immune Responses with Recombinant Lentivector: Role of Skin Derived DCs
Current Cancer Therapy Reviews Editorial (Thematic Issue: Improving Cancer Clinical Research and Trials with Hispanic Populations: Training and Outreach Efforts Between Moffitt Cancer Center and the Ponce School of Medicine)
Reviews on Recent Clinical Trials Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Induced Dyspepsia
Current Pharmaceutical Design